Hyperhomocysteinemia in Chronic Renal Failure: Alternative Therapeutic Strategies

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 191-194

  Perna, Alessandra F ^a   Sepe, Immacolata ^a   Lanza, Diana ^a   Pollastro, Rosa Maria ^a   De Santo, Natale G ^a   Ingrosso, Diego ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; FOLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DRUG RESISTANCE; HUMAN; HYPERHOMOCYSTEINEMIA; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ACETYLCYSTEINE; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 84855168925     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.008     Document Type: Article

References (22)

1. Abraham J.M., Cho L. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?. Cleve Clin J Med 2010, 77:911-918.
2. Perna A.F., Ingrosso D., Violetti E., et al. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin Dial 2009, 22:351-356.
3. Ingrosso D., Cimmino A., Perna A.F., et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uremia. Lancet 2003, 361:1693-1699.
4. Massy Z.A. Therapy of hyperhomocysteinemia in chronic kidney disease. Semin Nephrol 2006, 26:24-27.
5. Jamison R.L., Hartigan P., Kaufman J.S., et al. Veterans Affairs site investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
6. Heinz J., Kropf S., Domröse U., et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010, 121:1432-1438.
7. Qin X., Huo Y., Langman C.B., et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2011, 6:482-488.
8. Ducloux D., Aboubakr A., Motte G., et al. Hyperhomocysteinaemia therapy in hemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant 2002, 17:865-870.
9. Sengupta S., Chen H., Togawa T., et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001, 276:30111-30117.
10. Himmelfarb J., McMenamin E., McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002, 61:705-716.
11. Perna A.F., Ingrosso D., Lombardi C., et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003, 63:S137-S140.
12. Kleinova M., Belgacem O., Pock K., et al. Characterization of cysteinylation of pharmaceutical grade human serum albumin by electrospray ionization mass spectrometry and low-energy collision-induced dissociation tandem mass spectrometry. Rapid Commun Mass Spectrom 2005, 19:2965-2973.
13. Bar-Or D., Curtis C.G., Sullivan A., et al. Plasma albumin cysteinylation is regulated by cystathionine beta-synthase. Biochem Biophys Res Commun 2004, 325:1449-1453.
14. House A.A., Eliasziw M., Cattran D.C., et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010, 303:1603-1609.
15. Jacob J, Zahi R, Guarino P, Kaufman J. Potential adverse myocardial effects of B-vitamin therapy: lessons from the HOST trial. In: 8th International Congress on Homocysteine Metabolism. Lisboa, 19-22 June 2011:52.
16. Ventura P., Panini R., Pasini M.C., Scarpetta G., Salvioli G. N-acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol Res 1999, 40:345-350.
17. Scholze A., Ringer C., Beige J., Riezler R., Zidek W., Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse and endothelial function in patients with endstage renal failure. Circulation 2004, 1009:369-374.
18. Thaha M., Yogiantoro M., Tomino Y. Intravenous N-acetylcysteine during hemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease. Clin Drug Invest 2006, 26:195-202.
19. Soldini D., Zwahlen H., Gabutti L., Marzo A., Marone C. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur J Clin Pharmacol 2005, 60:859-864.
20. Nolin T.D., Ouseph R., Himmelfarb J., McMenamin M.E., Ward R.A. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol 2010, 5:1588-1594.
21. Tepel M., van der Giet M., Statz M., Jankowski J., Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 2003, 107:992-995.
22. Friedman A.N., Bostom A.G., Laliberty P., Selhub J., Shemin D. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomised, controlled study. Am J Kidney Dis 2003, 41:442-446.